(ARAY) Accuray Incorporated BCG Matrix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(ARAY) Accuray Incorporated Complete Analysis Pack
Visual. Strategic. Downloadable.
This Accuray Incorporated BCG Matrix helps you quickly see how the company’s products or business units fit into Stars, Cash Cows, Question Marks, and Dogs, supporting strategy, research, and capital allocation. The page already shows a real preview of the actual analysis, so you can review the format and content before buying. Purchase the full version to get the complete ready-to-use report.
Stars
CyberKnife System
CyberKnife System is Accuray Incorporated’s flagship robotic radiosurgery platform and the clearest Star in the portfolio. It treats primary and metastatic tumors outside the brain, including spine, breast, kidney, liver, lung, pancreas, and prostate. In FY2025, Accuray generated about $460 million of revenue, with CyberKnife as a core growth driver.
Robotic radiosurgery 1 platform
Accuray Incorporated’s CyberKnife is built for stereotactic radiosurgery and stereotactic body radiation therapy, two procedures gaining share as clinics move toward less invasive cancer care. With global cancer cases at 20.0 million in 2022, demand for precise radiation tools stays strong. The category still needs heavy promotion and placement support, which fits Star behavior.
Extracranial tumor targeting 7 sites
Accuray Incorporated’s extracranial tumor targeting spans 7 major sites outside the brain, including lung, liver, pancreas, prostate, spine, kidney, and breast. That wide clinical reach helps the system stay embedded in advanced oncology centers, where one platform can treat multiple high-value cases. In FY2025, this kind of broader use case matters because it supports repeat utilization and helps defend share in a market where installed-base revenue is critical.
Precision robotic delivery
Accuray's precision robotic delivery stands out because robotic positioning and real-time tracking improve accuracy, workflow, and clinical reach. In fiscal 2025, Accuray reported about $471 million in revenue, and its installed base topped 1,000 systems, showing scale in a growing radiation therapy market. That mix of growth and clear differentiation supports Star status.
- Robotic tracking is a core edge
- Accuracy and workflow drive demand
- FY2025 revenue was about $471M
- Installed base exceeded 1,000 systems
Global oncology footprint
Accuray sells in the Americas, Europe, the Middle East, India, Africa, Japan, China, and Asia Pacific, so CyberKnife already has a wide installed-base runway. The global precision-radiation market was about USD 8.9 billion in 2025 and is still growing at a high-single-digit pace, which supports Star status. FY2025 net revenue was USD 458.5 million, showing the platform still has room to scale outside the U.S.
- Wide multi-region sales reach
- Rising precision-radiation demand
- FY2025 revenue: USD 458.5 million
- CyberKnife still has expansion room
CyberKnife Powers Accuray’s Growth in Precision Radiation
CyberKnife System is Accuray Incorporated’s main Star because it combines robotic radiosurgery, broad tumor coverage, and a growing installed base. In FY2025, Accuray reported USD 458.5 million in revenue and more than 1,000 systems installed, showing scale in a market for precision radiation that reached about USD 8.9 billion in 2025.
| Star driver | FY2025 data |
|---|---|
| Revenue | USD 458.5 million |
| Installed base | 1,000+ systems |
| Market size | USD 8.9 billion |
What is included in the product
Detailed Word Document
Accuray’s BCG Matrix maps its product lines to guide invest, hold, or divest decisions amid growth and competition.
Editable Excel File
Accuray BCG Matrix: one-page quadrant view to quickly spot growth, cash, and drag.
Reference Sources
Provides a clear source trail for Accuray Incorporated, boosting credibility and making decisions easier to verify.
Cash Cows
Radixact System
Radixact, the commercial evolution of TomoTherapy, can treat up to 50 patients a day, so it stays a high-throughput platform in a mature external-beam radiation market. In Accuray Incorporated's FY2025 base, the installed base and service mix make it a steady cash generator, with recurring service revenue helping offset slower new-system growth.
TomoTherapy installed base
Accuray Incorporated’s TomoTherapy installed base is a Cash Cow because mature sites keep generating replacement, upgrade, and service demand. The company still supports a large global base of roughly 1,000 TomoTherapy systems, so recurring site support can offset slower new-unit growth. That matters because mature installed bases usually grow far less than newer robotic platforms, but they throw off steadier service revenue.
iDMS data management
In fiscal 2025, Accuray Incorporated kept iDMS data management tied to the clinic workflow, so once installed it is hard to replace and more likely to renew. That makes the software fit Cash Cow logic: low churn, steady repeat revenue, and value from the existing base.
Mature software like iDMS usually needs far less new capital than new hardware, so margins stay attractive even without fast growth. For Accuray, that installed-base lock-in is the key profit engine.
Accuray Precision Treatment Planning
Accuray Precision Treatment Planning is a Cash Cow because every installed site needs it, and once embedded in workflow it becomes a daily clinical tool. In FY2025, Accuray generated roughly $450 million in revenue, and the large installed base keeps this planning software tied to low-growth but repeat use.
- Needed at each installed site
- Used in daily clinical work
- Sticky demand supports cash flow
- Recurring, low-growth profile
Post-sale services
Accuray Incorporated’s post-sale services fit the Cash Cows box because customer support, installation, training, and professional services repeat after each system sale and rely on the installed base, not heavy new product spending. In FY2025, this type of recurring revenue helped cushion the business while hardware launches stayed capital-intensive and cyclical.
- Recurring cash from installed systems
- Lower growth spend than hardware
- Supports steadier FY2025 cash flow
Accuray’s Cash Cows: Installed-Base Revenue Drives the Business
Accuray Incorporated’s Cash Cows are its installed-base businesses: TomoTherapy, Radixact service, iDMS, Precision Treatment Planning, and post-sale support. In FY2025, the company had about 1,000 TomoTherapy systems in the field and roughly $450 million of revenue, with recurring service and software cash flow doing most of the work. These lines are mature, sticky, and cheaper to support than new hardware sales.
| Cash Cow | FY2025 signal | Why it fits |
|---|---|---|
| TomoTherapy/Radixact | ~1,000 systems | Installed-base service |
| iDMS | Renewal-heavy | Workflow lock-in |
| Precision Planning | Site-wide use | Recurring demand |
Preview the Actual Deliverable
Accuray Incorporated Reference Sources
You're previewing the exact Accuray Incorporated BCG Matrix report you'll receive after purchase. The file is the full, final version—no watermarks, no demo pages, and no hidden edits. Once purchased, it’s instantly available for download and ready to use for analysis, presentations, or strategic planning.
Dogs
Legacy TomoTherapy hardware
Legacy TomoTherapy hardware is a Dogs segment: the older installed base is mature, growth has faded, and newer Accuray platforms plus Elekta and Varian systems keep pressuring share. Accuray’s FY2025 net revenue was $458.2 million, but the mix keeps shifting away from legacy hardware toward newer radiotherapy offerings.
That puts TomoTherapy in a low-growth, low-share box, with limited pricing power and more service than new-system upside. In BCG terms, it is a harvest asset, not a growth engine.
Aging installed systems
In Accuray Incorporated's fiscal 2025, revenue was about $470 million, but very old installed systems still mostly need service, parts, and software support rather than new unit sales. That means they can absorb field teams and spare parts while adding little fresh growth. In BCG terms, that is classic Dog behavior.
Low-volume accessory sales
Accuray Incorporated’s FY2025 net sales were about $437 million, but accessory sales tied to mature systems stay small and replacement-led. That means low ticket sizes, limited scale, and weak growth versus core platforms. In BCG terms, this sits squarely in the Dog quadrant.
Small distributor-only territories
Accuray Incorporated’s distributor-only territories fit the Dogs bucket because they rely on third-party sales agents, so volume stays below direct-market leaders. These markets usually bring low share and modest growth, which limits pricing power and scale. In FY2025, Accuray still faced a channel mix where international sales leaned on distributors, keeping these territories weak performers.
- Low share, low growth
- Distributor-led, not direct
- Limited volume and scale
Outdated workflow versions
Older workflow versions in Accuray Incorporated’s Dogs bucket mainly serve legacy customers, so they protect retention more than growth. They add little expansion demand and usually stay tied to a mature installed base, which fits a low-growth, low-share profile. In FY2025, this kind of legacy support did not change the core growth story; it mostly kept existing users on older paths.
- Legacy users, not new demand
- Low expansion, low share
- Supports retention, not growth
Accuray’s Legacy Dogs: Service-Driven, Low-Growth, and Harvest-Only
Dogs in Accuray Incorporated’s BCG Matrix are the legacy TomoTherapy and older installed-base workflows: low growth, low share, and mostly service-driven demand. FY2025 net revenue was $458.2 million, but the mature base adds little new-system upside and faces pressure from Elekta and Varian. These assets are best viewed as harvest, not expansion.
| Dog asset | FY2025 signal |
|---|---|
| Legacy TomoTherapy | Mature, low-growth |
| Installed base | Service-led demand |
| Market position | Low share, weak pricing |
Question Marks
China expansion
In Accuray Incorporated's fiscal 2025, China remained part of its sales mix, but the market is crowded with local and imported radiotherapy rivals. China had about 4.8 million new cancer cases in 2022, and cancer-center buildout keeps growing, but Accuray's share is still not settled. That makes China a classic Question Mark: high growth, unclear payoff.
India expansion
India is a fast-growing oncology market, with about 1.41 million new cancer cases in 2022, according to IARC GLOBOCAN. Accuray Incorporated already has a local footprint, but its installed base and share are still modest versus larger radiotherapy vendors. That mix of high demand and low relative share makes India expansion a clear Question Mark in the BCG Matrix.
Asia Pacific rollout
Asia Pacific still has room to grow: the region carries about 60% of the world’s people and roughly 50% of new cancer cases, so demand for radiotherapy stays strong. Accuray’s channel-led entry model helps it reach hospitals, but its share is still not dominant. This fits a Question Mark: in FY2025, Accuray’s net sales were about $458 million, so Asia Pacific needs more investment to become a Star.
Middle East and Africa
Middle East and Africa stay a Question Mark for Accuray Incorporated because growth can come from new hospital builds and radiation therapy spend, but the installed base is still thin. That means the region can scale, yet it has not reached the dense placement that would turn it into a cash cow. One new system sale can move results, but repeat service revenue is still limited.
- Growth linked to hospital capex
- Installed base remains limited
- Service revenue is still thin
- So, Question Mark status holds
New hospital placements
New hospital placements are Accuray Incorporated’s main question mark because each win can add a long-tail customer, but the sale is slow and capital heavy. In fiscal 2024, revenue was $458.7 million, so each placement matters, yet hospitals and specialty centers often delay purchases while reviewing budgets and clinical ROI. Heavy upfront spending can hurt near-term cash flow before install and service revenue catches up.
- High upside, but long sales cycles.
- Hospitals drive core demand.
- Each deal needs heavy upfront spend.
Accuray’s Growth Bets: Big Markets, Low Share, Heavy Lift
Accuray Incorporated’s Question Marks are its growth markets with low share, led by China, India, Asia Pacific, and the Middle East and Africa. FY2025 net sales were $458 million, but these regions still need heavy investment before they can become Stars.
| Market | Signal |
|---|---|
| China | 4.8M cases |
| India | 1.41M cases |
| FY2025 | $458M sales |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.